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Abstract Heparin-binding epidermal growth factor-like growth
factor (HB-EGF), a potent mitogen and migration factor for
vascular smooth muscle cells (SMC), promoted neovasculariza-
tion in vivo in the rabbit cornea. MRI demonstrated quantita-
tively the angiogenic effect of HB-EGF when introduced
subcutaneously into nude mice. HB-EGF is not directly
mitogenic to endothelial cells but it induced the migration of
bovine endothelial cells and release of endothelial cell mitogenic
activity from bovine vascular SMC. This mitogenic activity was
specifically blocked by neutralizing anti-vascular endothelial
growth factor (VEGF) antibodies. In contrast, EGF or
transforming growth factor-K (TGF-K) had almost no effect on
release of endothelial mitogenicity from SMC. In addition, RT-
PCR analysis demonstrated that VEGF165 mRNA levels were
increased in vascular SMC 4^10-fold by 0.35^2 nM of HB-EGF,
respectively. Our data suggest that HB-EGF, as a mediator of
intercellular communication, may play a new important role in
supporting wound healing, tumor progression and atherosclerosis
by stimulating angiogenesis.
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1. Introduction
Angiogenesis, the growth of new capillary blood vessels by
sprouting from established vessels, is a normal process inher-
ent in embryogenesis, wound repair, ovulation and in various
pathologies, such as psoriasis, atherosclerosis and tumor
growth.
Angiogenesis is characterized by the migration and prolif-
eration of vascular endothelial cells and vascular smooth
muscle cells (SMC). The migration and proliferation of vas-
cular SMC and endothelial cells during angiogenesis is medi-
ated by speci¢c growth factors. Some of the best characterized
of these growth factors are platelet-derived growth factor
(PDGF), transforming growth factor-K (TGF-K), ¢broblast
growth factor (FGF) and vascular endothelial growth factor
(VEGF) [1,2]. VEGF is a particularly important endothelial
growth factor associated with tumor progression, wound heal-
ing and development. VEGF is a secreted, 46-kDa dimeric
protein active as a direct and speci¢c mitogen for vascular
endothelial cells and as an angiogenic growth factor [3,4].
VEGF appears to function as a key regulator of physiologic
as well as pathologic angiogenesis [5,6]. VEGF165 is the pre-
dominant isoform secreted by a variety of normal and trans-
formed cells [7]. Unlike the endothelial cell mitogens, basic
and acidic FGF [8,9] which lack a signal peptide, VEGF is
a secreted protein [4]. Therefore, VEGF has the potential to
be released by intact cells without the need for postulating cell
death or specialized transport mechanisms. VEGF mRNA
levels in SMC are induced by hypoxia, by PDGF-BB [10]
and by interleukin-1b, but not by epidermal growth factor
(EGF) [11].
More recently, heparin-binding EGF-like growth factor
(HB-EGF), a novel member of the EGF family, has been
shown to be associated with SMC migration and proliferation
[12,13], atherosclerosis [14,15], pregnancy [16,17], wound heal-
ing [18,19], and tumor development [15]. HB-EGF is synthe-
sized as a transmembrane precursor which is later processed
to the mature 86-amino acid form. Mature bioactive HB-EGF
is a well characterized 20^22-kDa glycoprotein that binds the
EGF receptor with high a⁄nity and stimulates its phosphoryl-
ation [12]. HB-EGF is a potent mitogen for ¢broblasts,
smooth muscle cells [12] and keratinocytes [18] but is not
mitogenic for endothelial cells [12]. HB-EGF is as active as
PDGF but considerably more potent than EGF and TGF-K
in stimulating bovine aortic SMC proliferation and migration
[12,13]. Since the formation of mature blood vessels requires a
concerted growth and migration of vascular SMC and endo-
thelial cells, the possibility was tested that HB-EGF, which is
a potent mitogen and migration factor for vascular SMC and
is present in atherosclerotic, tumor and injury sites, is also
angiogenic. We report here for the ¢rst time that HB-EGF
induces angiogenesis in vivo, that it induces endothelial cell
migration and that it mediates endothelial cell proliferation by
inducing VEGF expression and secretion by co-cultured vas-
cular SMC.
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2. Materials and methods
2.1. Materials
Neutralizing anti-HB-EGF polyclonal antibody 197 was raised in
goats by injection of a recombinant 77-amino acid form of human
HB-EGF. The antibody is speci¢c and does not neutralize EGF,
TGF-K or amphiregulin. Goat anti-human VEGF neutralizing anti-
bodies were purchased from RpD systems (Minneapolis, MN). Re-
combinant human HB-EGF consisted of residues 73^148 as predicted
from the nucleotide sequence of the HB-EGF precursor’s 208-codon
open reading frame, and was produced using an Escherichia coli ex-
pression system [20,21]. Human recombinant HB-EGF and neutraliz-
ing anti-human HB-EGF polyclonal antibody 197 were received from
Scios Inc. (Sunnyvale, CA). EGF and TGF-K were purchased from
Collaborative Biomedical Products (Bedford, MA). 77R is an anti-
bFGF polyclonal antibody raised in sheep and directed against the
recombinant 154-amino acid human basic FGF (bFGF) produced in
E. coli.
2.2. Cell lines
Brain bovine capillary endothelial cells (BCE), bovine aortic endo-
thelial cells (BAE) and vascular SMC were kindly provided by Prof.
Israel Vlodavsky (Hadassah Medical center, Jerusalem). BCE and
vascular SMC were cultured at 37‡C in low-glucose DMEM (1 g/l)
supplemented with 10% calf serum (HyClone, Logan, UT), a serum-
free supplement: biogro-1 (Beth Haemek, Israel), penicillin (100 U/
ml), streptomycin (0.1 mg/ml) (Biological Industries, Israel) and 2 mM
glutamine (Biolab Ltd. Israel) (GPS). Bovine aortic vascular smooth
muscle cells (SMC) were cultured in low-glucose DMEM (1 g/l) sup-
plemented with 10% fetal calf serum (HyClone) and GPS. For RNA
experiments, SMC were seeded in 100 mm diameter dishes at a density
of 1.6U105 cells/dish (approximately 20% con£uence). Medium was
changed after 24 h to starvation medium (DMEM with GPS) and 48 h
later HB-EGF was added at di¡erent concentrations for 24 h.
2.3. Reverse transcriptase-PCR analysis
RNA was isolated from SMC cells using TRI reagent [22] (Molec-
ular Research Center Inc., Cincinnati, OH). Complementary DNA
was synthesized from 300 ng of total RNA using oligo(dT) as a
primer and AMV reverse transcriptase. PCR ampli¢cation was carried
out in the presence of [32P]dCTP tracer (2 WCi in 100 Wl reaction
volume), 1 mM of each dNTP, 2.5 mM MgCl2, and 2.5 units of
Taq polymerase. Twenty-¢ve ampli¢cation cycles were used, of
1 min at 94‡C, 2 min at 65‡C and 3 min at 72‡C. The cDNAs were
co-ampli¢ed with oligonucleotides of VEGF (GGAGAGAT-
GAGCTTCCTACAG and TCACCGCCTTGGCTTGTCACA, cor-
responding to the coding region for amino acids 92^98 and the six
carboxy-terminal amino acids of VEGF, respectively); and L19 (serv-
ing as an internal standard, CTGAAGGTCAAAGGGAATGTG and
GGACAGAGTCTTGATGATCTC, corresponding to forward and
reverse sequences). Ampli¢ed fragments were resolved in 6% non-de-
naturing polyacrylamide gel and visualized by autoradiography. Ra-
dioactivity of the hybridization signal on the ¢lter was measured by
using a Fujix Bas 1000 Bioimaging Analyzer (Fuji, Japan).
2.4. Co-culture assay for SMC and BCE cells
SMC were seeded in 6-well plates (3U104 cells/well), where each
well contained a sterile round cover glass (18 mm diameter). BCE cells
were seeded in 24-well plates (5U103 cells/well), on sterile round cover
glass (13 mm diameter). Twenty-four hours following seeding, both
cell lines were starved for 48 h (DMEM with only GPS for SMC and
DMEM with GPS and 0.5% bovine serum albumin (BSA) for BCE).
After 48 h of starvation, the 18-mm cover glasses in 6-well plates were
replaced by new ones (exactly on the bald spot created by removing
the original cover glass). Smaller (13-mm) cover glasses with their
adherent BCE were removed from the 24-well plates and were placed
on top of the fresh 18-mm cover glasses in the 6-well plates together
but separated from the vascular SMC. Growth factors and neutraliz-
ing antibodies were then added in fresh medium for 30 h (in tripli-
cate). Neutralizing antibodies were added at concentrations of 10^13
Wg/ml. [3H]Methylthymidine 5 WCi/ml (ROTEM Ind. Ltd., Israel) was
added to the cells for the last 6 h of the 30 h co-culture period. The
cells were rinsed with 2 ml methanol for 10 min, followed by 2 ml 5%
cold trichloroacetic acid (TCA). Afterwards cells were washed with
water and glasses with BCE were removed to separate 24-well plates.
FEBS 20050 3-4-98
Fig. 1. HB-EGF promotes neovascularization in vivo in the rabbit cornea assay in a time- and dose-dependent manner. Photographs were tak-
en 4 days after injection (A^E), and 7 days after injection (F). The injection site is marked by asterisks. Corneal angiogenesis (between arrows)
is prominent in corneas injected with HB-EGF (D^F). PBS (A) served as a negative control. Basic FGF served as a positive control (C). EGF
(500 pmol) did not induce angiogenesis (B). n = 6. Bar length 0.5 cm.
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Cells were lysed with 0.5 M NaOH. Radioactive thymidine incorpo-
ration into DNA was determined in a L counter (LKB, WALLAC,
Finland). Experiments were performed at least twice. Control experi-
ments in which vascular SMC or BCE cells were incubated separately
in the presence of HB-EGF demonstrated that SMC were not found
on the cover glass and that BCE from the cover glass were not seen in
the well.
2.5. Migration assay for endothelial cells
Boyden chamber migration assays were performed as previously
described [23]. Collagen IV prepared from EHS tumors was dried
on a polycarbonate ¢lter (5 mg/¢lter) (PVP-free, Nucleopore, Pleas-
anton, CA). Fibroblast conditioned medium (obtained from con£uent
NIH-3T3 cells cultured in serum-free DMEM) was used as a positive
chemoattractant control. BCE or BAE cells were harvested by brief
exposure to 1 mM EDTA, washed with DMEM containing 0.1% BSA
and added to the Boyden chamber (2U105 cells). The chambers were
incubated in a humidi¢ed incubator at 37‡C in 5% CO2/95% air at-
mosphere for 6 h. The cells which traversed the collagen layer to the
side to which chemoattractants were added, and attached to the lower
surface of the ¢lter, were stained with Di¡ Quick (American Scienti¢c
Products) and counted. The results are the average of two independ-
ent experiments, each performed in duplicate.
2.6. Rabbit cornea assay for angiogenesis
New Zealand albino rabbits (weight 3 kg, males and females in
equal numbers) were used in our study. The animals were deeply
anaesthetized with 5 mg/kg xylasine and 35 mg/kg ketamine-HCl in-
jected intramuscularly. The rabbit eyes were treated with Localin, an
ophthalmic solution for surface anesthesia (Benoxinate HCl 0.4%,
Fisher, Pittsburgh, PA). Using a surgical microscope (Inami, Japan),
5 Wl of HB-EGF, bFGF or EGF in phosphate-bu¡ered saline (PBS)
were injected subepithelially into the cornea by using a 10-Wl Hamil-
ton syringe. The injection was done 3^4 mm away from the limbal
margin of the cornea towards its center. The area chosen was the
midline between the insertions of the recti muscles, superior and lat-
eral or medial, right or left eye respectively. After the injection a white
opaque elevation of epithelium could be observed. Experiments were
done in duplicate and repeated three times (each treatment consisted
of six animals: three males and three females).
2.7. MRI analysis of subcutaneous angiogenesis in nude mice
Spherical agarose beads of approximately 1 mm in diameter were
formed from 4% low gelling temperature agarose (Sigma) in PBS
containing HB-EGF or b-FGF. The candidate angiogenic compound
(5 Wl/bead) was warmed in sterile micro test tubes to 40‡C in a dry
bath for a few seconds. 10 Wl of agarose solution (6% in saline, 45‡C)
was then added to the 5 Wl of the angiogenic compound and beads
were formed above ice using a 20-Wl pipette tip. Mice were anesthe-
tized with a single dose of 75 mg/kg ketamine+3 mg/kg xylazine (i.p.)
and beads were implanted 1 cm away from the incision site as re-
ported previously for multicellular spheroids [24]. Experiments were
done in duplicate and repeated three times. MRI experiments were
performed on a horizontal 4.7-T Bruker-Biospec spectrometer using a
2-cm surface coil as reported previously [24,25]. Mice were anesthe-
tized as described above and placed supine with the bead located at
the center of the surface coil. Gradient echo images (slice thickness of
0.5^0.6 mm, repetition time of 100 ms, 256U256 pixels, in plane
resolution of 110 Wm) were acquired with echo times of 10.5 and 20
ms. Growth of the capillary bed was re£ected by reduction of the
mean intensity at a region of interest of 1 mm surrounding the agar-
ose bead. Angiogenic capacity of the implanted beads was evaluated
from the di¡erence between the apparent vessel density determined by
MRI (AVDMRI) of day 4 and that of day 1. Validation of the
method and derivation of the physical source of contrast have been
reported elsewhere [25].
2.8. Data processing
MRI data was analyzed on a Personal Iris work station (Silicon
Graphics, USA) with software from NMRi (TRIPOS). Statistical sig-
ni¢cance of treatments was determined using Student’s t-test or AN-
OVA.
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Fig. 2. HB-EGF promotes neovascularization in vivo in beads im-
planted subcutaneously in nude mice in a dose-dependent manner.
The angiogenic potential of HB-EGF in vivo is demonstrated 4
days after implantation, in skin specimens (A^C) and quantitatively
by MRI (D). PBS served as a negative control (A,D), while bFGF
(0.35 nmol/bead), as a positive control (C,D). HB-EGF at 0.75^1.1
nmol/bead induced a signi¢cant dose-dependent neovascularization
around the beads (B,D). n = 8. Bar length 0.5 mm.
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3. Results
3.1. HB-EGF induces angiogenesis in the rabbit cornea
The angiogenic capacity of HB-EGF was demonstrated in
vivo in the rabbit cornea assay. Human recombinant HB-
EGF (70^210 pmol) was introduced subepithelially into the
rabbit cornea with minimal damage to the cornea. Two to
three days following introduction of HB-EGF into the cornea,
new blood vessels began to grow, in a dose-dependent man-
ner, from the limbal margin of the cornea towards the injec-
tion site. HB-EGF at low doses (70 pmol) was able to induce
neovascularization in the cornea within 4 days after introduc-
tion (Fig. 1D). A higher dose of HB-EGF (210 pmol) induced
an even more rapid and intense neovascularization 4 days
after introduction (Fig. 1E). Blood vessels continued to
grow and to develop and became larger and longer at 7
days after HB-EGF introduction (Fig. 1F). The rabbit eyes
were clear with no evidence of non-speci¢c in£ammation. PBS
alone as a negative control or even 500 pmol of EGF did not
induce any new blood vessel formation (Fig. 1A,B). To elim-
inate the possibility that the angiogenic reaction was due to
traces of endotoxin or reaction to a foreign protein, we intro-
duced boiled HB-EGF (210 pmol) and found no angiogenic
response (not shown). The angiogenic response of 210 pmol of
HB-EGF was comparable with that of 70 pmol of bFGF (Fig.
1C). Interestingly, when HB-EGF was repeatedly introduced
into the cornea with a 1-month interval between the introduc-
tions, even doses as low as 6^20 pmol of HB-EGF induced
new blood vessel formation (not shown).
3.2. HB-EGF induces angiogenesis in the skin
The angiogenic capacity of HB-EGF was also examined in
nude mice by subcutaneous implantation of agarose beads
containing HB-EGF, bFGF or PBS. The beads were im-
planted at a distance of 1 cm from the incision through which
they were introduced, to avoid an e¡ect resulting from injury.
Neovascularization around the beads was evaluated by sub-
traction of the apparent vessel density (AVDMRI) measured
on day 1 from that measured on day 4 by MRI. PBS, a
negative control, did not cause neovascularization around
the bead (Fig. 2A,D), while bFGF (0.35 nmol), a known
and potent angiogenic factor, caused signi¢cant neovasculari-
zation around the beads (Fig. 2C,D). In comparison, HB-
EGF also caused signi¢cant dose-dependent neovasculariza-
tion around the beads at 0.75^1.1 nmol doses (Fig. 2D).
HB-EGF induced a comparable angiogenic e¡ect to bFGF.
Both HB-EGF and bFGF induced an apparent yellowish col-
or inside and around the bead (Fig. 2B,C) which may be
related to increased leakage of plasma substances from the
nearby vessels.
3.3. HB-EGF induces endothelial cell migration
EGF, TGF-K and HB-EGF share 35% sequence homology
and bind to the EGF receptor. EGF and TGF-K were previ-
ously shown to be potent migration stimulating factors for
endothelial cells [26]. We have examined in Boyden chambers
the migration-stimulating capacity of HB-EGF and compared
it with that of EGF and TGF-K. Capillary as well as aortic
endothelial cells responded similarly and migrated in response
to HB-EGF in a dose-dependent manner (Fig. 3). At concen-
trations of 0.3^2.4 nM, HB-EGF induced a 3^13-fold increase
in endothelial cell migration, respectively (Fig. 3). At equimo-
lar concentrations, the migration stimulated by HB-EGF was
similar to that induced by EGF and TGF-K.
3.4. HB-EGF induces VEGF secretion by SMC, leading to
enhanced DNA synthesis in endothelial cells
It was previously shown that HB-EGF is a potent mitogen
for vascular SMC ¢broblasts and keratinocytes, but not for
endothelial cells. To reconcile the di¡erent activities of HB-
EGF in vivo and in vitro with respect to angiogenesis, we
have postulated that vascular SMC might be involved in
HB-EGF’s angiogenic e¡ect in vivo by inducing the prolifer-
ation of endothelial cells. We developed an assay in which
serum-starved BCE were co-cultured with serum-starved,
HB-EGF-treated SMC without contact between the two cell
types, and could thus measure whether there was a release of
an endothelial mitogenic activity from the induced SMC. In-
deed, when vascular SMC were co-cultured with endothelial
cells, HB-EGF induced an increase in DNA synthesis in BCE
cells in a dose-dependent manner, compared with non-induced
SMC (Fig. 4) as well as in BAE (not shown). At a concen-
tration as low as 7 pM, HB-EGF increased DNA synthesis in
BCE approximately 1.9-fold compared with non-treated con-
FEBS 20050 3-4-98
Fig. 4. HB-EGF induces secretion of an endothelial cell mitogen by
vascular SMC. DNA synthesis was measured in BCE co-cultured
with (empty circles) or without (full squares) vascular SMC in pres-
ence of various concentrations of HB-EGF as described in Section
2.
Fig. 3. HB-EGF induces endothelial cell migration. The migration
response of BCE and BAE cells to HB-EGF, EGF and TGF-K was
examined in Boyden chambers for 6 h. Conditioned medium (CM),
obtained from con£uent NIH-3T3 cells cultured in serum-free
DMEM, served as a positive control.
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trol (Fig. 4). HB-EGF alone had no e¡ect on DNA synthesis
in BCE (Fig. 4). The e¡ect of HB-EGF is speci¢c, since most
of it (90%) is blocked in the presence of neutralizing anti-HB-
EGF antibodies both for SMC and BCE in the co-culture
assay (Fig. 5A,B). At 70 pM HB-EGF increased DNA syn-
thesis in co-cultured BCE 3-fold, compared with BCE co-cul-
tured with non-treated SMC. EGF or TGF-K had almost no
e¡ect on DNA synthesis in the co-cultured BCE (Fig. 5A). In
contrast, the e¡ect of these three growth factors on DNA
synthesis in SMC themselves was similar under these condi-
tions: HB-EGF (70 pM) increased DNA synthesis 2.5-fold,
while TGF-K and EGF (140 pM) increased DNA synthesis
2.5- and 2.1-fold respectively (Fig. 5B). In order to identify
the secreted mitogenic activity for BCE which is induced in
HB-EGF-stimulated SMC we used neutralizing anti-VEGF
and neutralizing anti-bFGF antibodies. Neutralizing antibody
against bFGF suppressed only 25% of the endothelial cell
mitogenic e¡ect induced by HB-EGF, while neutralizing
anti-VEGF antibodies suppressed almost all the mitogenic
e¡ect of HB-EGF on BCE co-cultured with vascular SMC
(Fig. 5A). Neutralizing anti-VEGF antibodies had no e¡ect,
however, on the mitogenicity of HB-EGF for SMC (Fig. 5B).
This demonstrates that the major endothelial cell mitogen
secreted from HB-EGF-induced vascular SMC is VEGF.
The speci¢city of the anti-VEGF antibodies was assessed by
measuring DNA synthesis in BCE cells incubated with 5 ng/
ml hVEGF or 1 ng/ml of bFGF in presence of medium de-
rived from control non-treated vascular SMC. Neutralizing
anti-VEGF antibodies inhibited most (75%) of the 3-fold in-
crease in DNA synthesis induced in BCE cells incubated with
hVEGF while they had almost no e¡ect (15%) on the 3-fold
increase in DNA synthesis induced in BCE by bFGF (not
shown).
3.5. Induction of VEGF mRNA level in SMC by HB-EGF
To examine whether HB-EGF a¡ects VEGF expression in
vascular SMC, RNA was extracted from SMC exposed to
HB-EGF for 24 h and steady-state levels of VEGF mRNA
were compared with non-induced cells by RT-PCR analysis.
VEGF165 mRNA levels were markedly increased in vascular
SMC by HB-EGF. VEGF165 was the predominant form de-
tected in this assay. Quantitation by Bioimaging Analyzer of
the VEGF165 mRNA, normalized versus the internal standard
ribosomal L19, demonstrated a 4^10-fold increase by 0.35^2
nM of HB-EGF, respectively (Fig. 6). Interestingly, VEGF is
also expressed, although at low levels, in non-induced vascular
SMC, reinforcing our observation that non-induced SMC re-
lease endothelial cell mitogenic activity (Fig. 4), possibly
through an HB-EGF autocrine loop.
4. Discussion
Angiogenesis plays an important role in wound healing,
pregnancy, tumor progression and atherosclerosis [1,2,27]. Ac-
tivated monocyte-macrophages are key angiogenesis e¡ectors
in these settings [1,27]. HB-EGF, a recently described member
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Fig. 6. HB-EGF induces the level of VEGF mRNA in vascular
smooth muscle cells. RNA was prepared from control non-treated
SMC and SMC treated for 24 h with 0.35 nM and 2 nM HB-EGF.
VEGF mRNA levels were compared by RT-PCR analysis. Ampli-
¢ed VEGF cDNA fragment corresponds to mRNA of VEGF165.
Co-ampli¢ed ribosomal L19 served as an internal standard.
Fig. 5. HB-EGF induces secretion of VEGF by vascular SMC. Vas-
cular SMC were co-cultured with BCE. Cell proliferation was moni-
tored by [3H]thymidine incorporation into BCE cells (A) or SMC
(B) in comparison with non-treated cells. The e¡ect of neutralizing
antibodies against HB-EGF, VEGF or bFGF on the enhancing ef-
fect of HB-EGF on co-cultured BCE cells (A) or SMC (B) was ex-
amined. In comparison to HB-EGF, TGF-K and EGF had almost
no e¡ect on the co-cultured BCE cells (A). Actual [3H]thymidine in-
corporation into BCE cells was 5500 cpm when incubated with con-
trol vascular SMC and 16 600 cpm when incubated with vascular
SMC primed with 70 pM HB-EGF.
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of the EGF family, is synthesized by in£ammatory cells, in-
cluding monocytes, macrophages [12,28] and T lymphocytes
[15,29], and has been shown to be associated with atheroscle-
rosis [14,15], tumor development [15], pregnancy [17] and with
wound healing as the major heparin-binding growth factor
for ¢broblasts and keratinocytes present in wound £uid
[18,19].
In this study we show for the ¢rst time that HB-EGF pro-
motes neovascularization in vivo in the rabbit cornea assay in
a time- and dose-dependent manner, at doses as low as 70
pmol, and can thus be considered a novel angiogenic factor.
At 210 pmol HB-EGF induced a comparable angiogenic ac-
tivity in our rabbit cornea assay as bFGF at a dose of 70
pmol. On the other hand, EGF, which has weak angiogenic
properties, did not induce angiogenesis in our rabbit cornea
assay even at a dose of 500 pmol. In comparison, tumor
necrosis factor type K (TNF-K), a known angiogenic factor,
was previously shown to stimulate neovascularization in the
rabbit cornea assay at doses of 300 pmol, while bFGF pro-
duced neovascularization in that report at 30 pmol [30]. In
addition, by using MRI we have been able to demonstrate
quantitatively the angiogenic capacity of HB-EGF introduced
subcutaneously into nude mice. Similar to the rabbit cornea
assay, in the MRI assay bFGF had an angiogenic activity
comparable to that of HB-EGF. To our knowledge, this is
the ¢rst time MRI has been used to study a new angiogenic
factor in vivo in a non-invasive way.
Ushiro et al. recently reported that HB-EGF binds to the
EGF receptor on human microvascular endothelial cells and
induces the formation of tube-like structures in type I collagen
gel in vitro [31]. These ¢ndings in human microvascular endo-
thelial cells demonstrate another property of HB-EGF which
may be important for its activity as an angiogenic factor in
vivo.
HB-EGF does not induce proliferation of endothelial cells
[12]. The question was raised as to what may then be the
mechanism of the angiogenic activity of HB-EGF that we
observed in vivo. The factors EGF and TGF-K were previ-
ously shown to be angiogenic in vivo [32] and to be among the
most potent migration factors to endothelial cells [26,33]. Ex-
amination of the migration-stimulating potential of HB-EGF
for endothelial cells demonstrates, for the ¢rst time, that it is
as potent as EGF and TGF-K.
Formation of mature blood vessels requires a concerted
growth and migration of vascular SMC and endothelial cells.
It was recently shown that the reciprocal interactions between
endothelium and surrounding mesenchyme and smooth
muscle cells is crucial for the normal development of veins
mainly through angiopoietin-1 and the TIE2 receptor [34^
36]. The ability of HB-EGF to stimulate vascular SMC
growth and migration [12,13] suggests a possible role in blood
vessel development. We have demonstrated that HB-EGF is
an indirect endothelial cell mitogen, via its e¡ect on SMC.
It was shown previously that aortic SMC express and se-
crete VEGF165 [37,38]. In the present study we demonstrate
that HB-EGF induces a marked concentration-dependent in-
crease (4^10-fold) in the VEGF165 mRNA level in vascular
SMC. In addition we show that neutralizing anti-VEGF anti-
bodies block most of the endothelial mitogenic activity se-
creted by HB-EGF-stimulated vascular SMC in vitro. These
results suggest that the angiogenic e¡ect of HB-EGF in vivo is
mediated by inducing the migration of both endothelial and
vascular smooth muscle cells without contact between the two
cell types, as well as by the induction of VEGF in vascular
SMC, and that this VEGF then acts on neighboring endothe-
lial cells in a paracrine manner to induce proliferation and
blood vessel formation. Since endothelial cell proliferation
can be inhibited by contact with SMC and pericytes [39] it
is possible that the e¡ect of HB-EGF on the interaction be-
tween these two cell types when direct contact between them is
made, may be di¡erent. EGF and TGF-K were as potent as
HB-EGF in inducing endothelial cell migration, but had al-
most no e¡ect on inducing release of endothelial mitogenic
activity from vascular SMC. This is in agreement with our
data that EGF, which is known to be a weak angiogenic
factor, was not angiogenic in the rabbit cornea assay at a
dose of 500 pmol, as well as with a previous ¢nding that
EGF does not induce VEGF mRNA in vascular SMC [11].
HB-EGF is a much more potent angiogenic factor than EGF
in vivo. This potency may re£ect the fact that unlike EGF,
HB-EGF induces VEGF in vascular SMC.
The expression of HB-EGF at tumor and atherosclerosis
sites in macrophages and T lymphocytes [14,15] suggests
that these in£ammatory cells may be the source for HB-
EGF in these sites of intense angiogenesis. However, HB-
EGF is also induced in several other cell types and other
processes in which angiogenesis is involved, such as in the
tubular epithelial cells in kidneys after ischemic injury [40],
in cancer cells [41^45], in vascular SMC [46^48], and in vas-
cular endothelial cells [49]. The source for HB-EGF as an
angiogenic mediator may thus vary for the di¡erent tissues
and processes.
VEGF was suggested to be involved in the maintenance of
vascular endothelial cells by being released from vascular
SMC [37,50] and was shown to be a survival factor in vivo
[51]. HB-EGF is produced by both vascular endothelial cells
and vascular SMC [46^49]. In accordance, HB-EGF is pro-
duced in normal arteries mainly in the endothelium and only
faintly in medial SMC [52]. Being expressed by the two cell
types constituting the blood vessel wall, HB-EGF may induce
the expression of VEGF in vascular SMC in either a paracrine
or autocrine manner and contribute to the maintenance of
vascular endothelial cells in the blood vessel wall.
In conclusion, our study demonstrates that HB-EGF is a
potent angiogenic factor in vivo and that it induces both
migration of endothelial cells and the expression and secretion
of VEGF in cultured SMC. This suggests a new role for HB-
EGF in normal and pathological neovascularization and in
vascular maintenance. Since HB-EGF has been shown to be
associated with wound healing [18,19], liver regeneration [53],
atherosclerosis [14,15] and tumor development [15], we sug-
gest that HB-EGF may contribute to angiogenesis in these
processes.
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